Controlled release implant dosage forms for cardiac arrhythmias: Review and perspectives

Drug Delivery
R J LevyJ Davis

Abstract

Cardiac implants using drug-polymer systems for the release of anti-arrhythmic agents directly to the myocardium have been successfully utilized in experimental studies for preventing and treating arrhythmias. This approach is hypothesized to be optimal since anti-arrhythmic agents are provided directly to the heart, and therefore the possibility of systemic side effects is reduced. Furthermore, anti-arrhythmic agents with poor oral bioavailability or with first-pass clearance characteristics following intravenous administration, such as the class III agent ibutilide, are optimally used by the direct cardiac route of administration. Cardiac controlled release implants have been demonstrated to be effective for optimizing the therapy of ventricular tachycardia, ventricular fibrillation, and atrial flutter. Monolithic matrices have been used for fixed rate release kinetics, and modulation of release has been possible through the use of iontophoretic drug delivery systems. Future implants will interface with forefront strategies in tissue engineering and molecular genetics to provide optimal therapy of the diseased arrhythmogenic myocardium.

References

Aug 1, 1992·Pacing and Clinical Electrophysiology : PACE·H Mond, N Strathmore
Sep 28, 1990·Science·R Langer
May 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·E R EdelmanM J Karnovsky
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J KostR Langer
Mar 1, 1987·Journal of Biomedical Materials Research·E R EdelmanR Langer
Jan 1, 1985·Journal of Biomedical Materials Research·E R EdelmanR Langer
Jul 1, 1995·Clinical Pharmacokinetics·V Labhasetwar, R J Levy
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·V LabhasetwarR J Levy
Nov 1, 1994·Pacing and Clinical Electrophysiology : PACE·P P KarpawichM Factkor
Jan 1, 1994·Journal of Electrocardiology·A Polikaitis, R Arzbaecher
Jan 1, 1993·Journal of Biomaterials Science. Polymer Edition·M Machluf, J Kost

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.